Biohaven Pharmaceuticals and XVIVO teamed up again, this time to create a mechanism of action animation for BHV-7000, their recently-acquired Kv7 activator. The BHV-7000 molecule blocks the action of the voltage-gated Kv7 potassium ion channel, which exquisitely regulates the excitability of neurons in the central nervous system.
To help neurologists understand the potential utility of a therapy such as BHV-7000, the scientific animation first reviewed what happens in diseases such as epilepsy, that have an imbalance between excitation and inhibition of neurons, which can cause excessive depolarization of the neurons.
Once BHV-7000 binds to the Kv7 ion channel, it activates the channel to increase the flow of potassium ions out of the cell. This causes the neural membrane to become hyperpolarized, which increases the threshold for firing another action potential and makes the neuron less likely to depolarize.
Biohaven chose a lengthier scope of animation for this project, over 4 and a half minutes, so the viewer could get a deeper dive into the science and burden behind the disease, the molecule, and the downstream effects of its action. Targeting Kv7 for antiseizure treatment may provide a new way to manage epilepsy.
See how XVIVO can transform your scientific data into a MOA animation with a consultation today: https://xvivo.com/contact-us/